Dynamic dual-tracer MRI-guided fluorescence tomography to quantify receptor density in vivo

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 22, 2013, Pages 9025-9030

  Davis, Scott C ^a   Samkoe, Kimberley S ^b   Tichauer, Kenneth M ^a,c   Sexton, Kristian J ^a   Gunn, Jason R ^a   Deharvengt, Sophie J ^d   Hasan, Tayyaba ^a   Pogue, Brian W ^a,b,e  

^a DARTMOUTH COLLEGE   (United States)

^b Departments of Medicine   (United States)

^c Illinois Institute of Technology   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Engineered proteins; Molecular imaging; Oncology; Optical imaging; Spectroscopy

Indexed keywords

AFFIBODY EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY IMAGING AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORESCENT DYE; GADOLINIUM; TRACER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; COMPARTMENT MODEL; CONTROLLED STUDY; COUPLED FLUORESCENCE MOLECULAR TOMOGRAPHY; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG UPTAKE; EX VIVO STUDY; FLUORESCENCE IMAGING; GENE OVEREXPRESSION; GLIOMA; IMAGE ANALYSIS; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN ENGINEERING; RECEPTOR DENSITY;

ENGINEERED PROTEINS; MOLECULAR IMAGING; ONCOLOGY; OPTICAL IMAGING; SPECTROSCOPY;

ANIMALS; FLUORESCENCE; GLIOMA; KINETICS; MAGNETIC RESONANCE IMAGING; MICE; MOLECULAR IMAGING; PROTEIN BINDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CELL SURFACE; TOMOGRAPHY, OPTICAL;

MUS;

EID: 84878436467     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1213490110     Document Type: Article

References (51)

1. Deschoolmeester V, Baay M, Specenier P, Lardon F, Vermorken JB (2010) A review of the most promising biomarkers in colorectal cancer: One step closer to targeted therapy. Oncologist 15(7):699-731.
2. Rosen MJ, Heniford BT (2005) Endoluminal gastric surgery: The modern era of minimally invasive surgery. Surg Clin North Am 85(5):989-1007.
3. Sharma SV, Settleman J (2010) Exploiting the balance between life and death: Targeted cancer therapy and "oncogenic shock." Biochem Pharmacol 80(5):666-673.
4. van't Veer LJ, Bernards R (2008) Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452(7187):564-570.
5. Samkoe Ks, et al. (2012) High vascular delivery of EGF, but low receptor binding rate is observed in AsPC-1 tumors as compared to normal pancreas. Mol Imaging Biol 14: 472-479.
6. Gerlinger M, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883-892.
7. Gambhir SS (2002) Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2(9):683-693.
8. James ML, Gambhir SS (2012) A molecular imaging primer: Modalities, imaging agents, and applications. Physiol Rev 92(2):897-965.
9. Massoud TF, Gambhir SS (2003) Molecular imaging in living subjects: Seeing fundamental biological processes in a new light. Genes Dev 17(5):545-580.
10. Weissleder R, Mahmood U (2001) Molecular imaging. Radiology 219(2):316-333.
11. Weissleder R, Ntziachristos V (2003) Shedding light onto live molecular targets. Nat Med 9(1):123-128.
12. Jain RK (2001) Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 46(1-3):149-168.
13. Orcutt KD, Rhoden JJ, Ruiz-Yi B, Frangioni JV, Wittrup KD (2012) Effect of smallmolecule-binding affinity on tumor uptake in vivo: A systematic study using a pretargeted bispecific antibody. Mol Cancer Ther 11(6):1365-1372.
14. Schmidt MM, Wittrup KD (2009) A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 8(10):2861-2871.
15. Thurber GM, Schmidt MM, Wittrup KD (2008) Factors determining antibody distribution in tumors. Trends Pharmacol Sci 29(2):57-61.
16. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4(3 Pt 1):153-158.
17. Logan J, et al. (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16(5):834-840.
18. Jain RK (2005) Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307(5706):58-62.
19. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 65(1-2): 271-284.
20. Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6(8):583-592.
21. Tichauer KM, et al. (2012) In vivo quantification of tumor receptor binding potential with dual-reporter molecular imaging. Mol Imaging Biol 14(5):584-592.
22. Leuschner F, et al. (2011) Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 29(11):1005-1010.
23. Lin Y, Thayer D, Nalcioglu O, Gulsen G (2011) Tumor characterization in small animals using magnetic resonance-guided dynamic contrast enhanced diffuse optical tomography. J Biomed Opt 16(10):106015.
24. Corlu A, et al. (2007) Three-dimensional in vivo fluorescence diffuse optical tomography of breast cancer in humans. Opt Express 15(11):6696-6716.
25. Milstein AB, et al. (2003) Fluorescence optical diffusion tomography. Appl Opt 42(16): 3081-3094.
26. Ntziachristos V, et al. (2004) Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V-Cy5.5 conjugate. Proc Natl Acad Sci USA 101(33):12294-12299.
27. Ntziachristos V, Tung CH, Bremer C, Weissleder R (2002) Fluorescence molecular tomography resolves protease activity in vivo. Nat Med 8(7):757-760.
28. Ntziachristos V, Weissleder R (2001) Experimental three-dimensional fluorescence reconstruction of diffuse media by use of a normalized Born approximation. Opt Lett 26(12):893-895.
29. Davis SC, et al. (2007) Image-guided diffuse optical fluorescence tomography implemented with Laplacian-type regularization. Opt Express 15(7):4066-4082.
30. Davis SC, et al. (2010) Comparing implementations of magnetic-resonance- guided fluorescence molecular tomography for diagnostic classification of brain tumors. J Biomed Opt 15(5):051602-051610.
31. Hyde D, et al. (2009) Hybrid FMT-CT imaging of amyloid-beta plaques in a murine Alzheimer's disease model. Neuroimage 44(4):1304-1311.
32. Kepshire D, et al. (2009) A microcomputed tomography guided fluorescence tomography system for small animal molecular imaging. Rev Sci Instrum 80(4):043701.
33. Lin Y, et al. (2011) A photo-multiplier tube-based hybrid MRI and frequency domain fluorescence tomography system for small animal imaging. Phys Med Biol 56(15): 4731-4747.
34. McCann CM, et al. (2009) Combined magnetic resonance and fluorescence imaging of the living mouse brain reveals glioma response to chemotherapy. Neuroimage 45(2): 360-369.
35. Gibbs-Strauss SL, et al. (2010) Detecting epidermal growth factor receptor tumor activity in vivo during cetuximab therapy of murine gliomas. Acad Radiol 17(1):7-17.
36. Carpenter G (1987) Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 56(1):881-914.
37. Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 7(10):2958-2970.
38. Marshall J (2006) Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107(6):1207-1218.
39. Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21(14):2787-2799.
40. Ciardiello F, et al. (1996) Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst 88(23):1770-1776.
41. Friedman M, et al. (2008) Directed evolution to low nanomolar affinity of a tumortargeting epidermal growth factor receptor-binding affibody molecule. J Mol Biol 376(5):1388-1402.
42. Lammertsma AA, et al. (1996) Comparison of methods for analysis of clinical [11C] raclopride studies. J Cereb Blood Flow Metab 16(1):42-52.
43. Zhou M, et al. (1993) Real-time measurements of kinetics of EGF binding to soluble EGF receptor monomers and dimers support the dimerization model for receptor activation. Biochemistry 32(32):8193-8198.
44. van de Ven S, et al. (2010) A novel fluorescent imaging agent for diffuse optical tomography of the breast: First clinical experience in patients. Mol Imaging Biol 12(3): 343-348.
45. Davis SC, et al. (2008) Magnetic resonance-coupled fluorescence tomography scanner for molecular imaging of tissue. Rev Sci Instrum 79(6):064302.
46. Davis SC, et al. (2010) MRI-coupled fluorescence tomography quantifies EGFR activity in brain tumors. Acad Radiol 17(3):271-276.
47. Segars WP, Tsui BMW, Frey EC, Johnson GA, Berr SS (2004) Development of a 4-D digital mouse phantom for molecular imaging research. Mol Imaging Biol 6(3): 149-159.
48. Mansfield JR, Gossage KW, Hoyt CC, Levenson RM (2005) Autofluorescence removal, multiplexing, and automated analysis methods for in-vivo fluorescence imaging. J Biomed Opt 10(4):41207.
49. Xu H, Kuo C, Rice B (2008) Improved sensitivity by applying spectral unmixing prior to fluorescent tomography. Biomedical Optics (BIOMED) (Optical Society of America, St. Petersburg, FL).
50. Zacharakis G, Favicchio R, Simantiraki M, Ripoll J (2011) Spectroscopic detection improves multi-color quantification in fluorescence tomography. Biomed Opt Express 2(3):431-439.
51. Dehghani H, et al. (2008) Near infrared optical tomography using NIRFAST: Algorithm for numerical model and image reconstruction. Commun Numer Methods Eng 25(6): 711-732.